Medical Department, Eli Lilly Italia S.p.A., Sesto Fiorentino, Florence, Rome, Italy.
CNS Neurosci Ther. 2012 Feb;18(2):110-8. doi: 10.1111/j.1755-5949.2010.00225.x. Epub 2010 Dec 28.
In patients with bipolar disorder, medication is effective in preventing relapses. Unfortunately, adherence to treatment in bipolar disorder, as in other chronic or recurrent conditions, is not optimal. Estimates of nonadherence to prescribed treatment range from 30% to 60% in epidemiological studies, and are at around 30% in clinical trials. Adherence to treatment is a potent predictor of effectiveness, both in clinical trials and cohort studies, therefore is a very relevant area of investigation. This study will try to show a picture of the real life care where adherence is influenced by a wide range of variables.
Prospective, observational, multicenter study in 650 adult patients with bipolar disorder, who had to initiate or change their treatment regimen, observed for 1 year. Adherence was measured by the Simplified Medication Adherence Questionnaire (SMAQ). Additional variables: Symptom severity, Montgomery-Åsberg Depression Rating Scale (MADRS), Young Mania Rating Scale (YMRS), Clinical Global Impression-Bipolar Disorder (CGI-BD), the Drug Attitude Inventory score (DAI-30), and quality of life (EuroQoL 5 Dimensions). The variables were recorded every 3 months for the next year.
Most subjects were out-patients (77.1%), female (58.8%), aged 31-50 years (50.1%) and overweight (41.8%) or obese (28.7%); 67.4% had type I bipolar disorder and 66.8% had depressive or mixed symptoms. Adherence was 39.9% at baseline (and increased up to 67.0% at completion. The main predictors of nonadherence were alcohol consumption, severe bipolar symptoms, young age at time of first treatment, negative attitude towards treatment.
The patient population of this observational trial was representative of the patients changing their therapy for bipolar disorder seen in clinical practice in Italy. Lack of adherence to pharmacotherapy for bipolar disorder is a serious issue, which is more likely to arise in alcohol users and patients with severe symptoms, negative attitude towards medication and/or initiation of treatment early in life. The findings could lead to a more adequate approach of adherence in patients with bipolar disorders.
在双相情感障碍患者中,药物治疗可有效预防复发。然而,双相情感障碍患者与其他慢性或复发性疾病患者一样,治疗依从性并不理想。在流行病学研究中,不遵医嘱服药的比例估计在 30%至 60%之间,而临床试验中的比例约为 30%。治疗依从性是临床试验和队列研究中疗效的有力预测因素,因此是一个非常相关的研究领域。本研究将尝试展示一个真实的生活护理画面,其中依从性受到广泛变量的影响。
这是一项前瞻性、观察性、多中心研究,共纳入 650 名成年双相情感障碍患者,这些患者需要开始或改变他们的治疗方案,观察期为 1 年。采用简化用药依从性问卷(SMAQ)来衡量依从性。其他变量包括:症状严重程度、蒙哥马利-阿斯伯格抑郁评定量表(MADRS)、杨氏躁狂评定量表(YMRS)、临床总体印象-双相障碍(CGI-BD)、药物态度量表(DAI-30)和生活质量(EuroQoL 5 维度)。在接下来的 1 年内,每 3 个月记录一次这些变量。
大多数患者为门诊患者(77.1%),女性(58.8%),年龄 31-50 岁(50.1%),超重(41.8%)或肥胖(28.7%);67.4%为 I 型双相情感障碍,66.8%有抑郁或混合症状。基线时的依从性为 39.9%(完成时增加至 67.0%)。不依从的主要预测因素是饮酒、严重的双相情感障碍症状、首次治疗时年龄较小、对治疗的消极态度。
这项观察性试验的患者人群代表了意大利临床实践中正在改变双相情感障碍治疗方案的患者。双相情感障碍患者药物治疗依从性差是一个严重的问题,在饮酒者和症状严重、对药物持消极态度以及年轻时开始治疗的患者中更有可能出现。这些发现可能会导致对双相情感障碍患者的依从性进行更恰当的处理。